García D, Paoletti M, Paoletti E, Ferreras R, Suárez-González L, Soto J, Aloni R

Language: Spanish
References: 24
Page: 3-10
PDF size: 450.51 Kb.

ABSTRACT

Background: Thrombofilic factors in women are cause of morbidity and mortality during pregnancy and puerperium.
Objective: To study the relationship of thrombophilic factors with recurrent miscarriages and deep venous thrombosis at the puerperium.
Material and method: A retrospective case-control study was done with the database of Clinic Laboratory and Hematology Service at 25 de Mayo Clinic and the Regional Center of Hemotherapy at Mar del Plata city, Argentina. Cases group included women with recurrent miscarriages and deep venous thrombosis at puerperium attending at 25 de Mayo Clinic during the period 2007-2009. Control group included women who were regular blood donors without history of recurrent miscarriages or deep venous thrombosis at the same period in the Regional Center of Hemotherapy of the city and pared by the same age. The main measure was the existence or not of thrombophilic factors.
Results: The lupic inhibitor was the acquired thrombophilic factor with greater statistical significance (p=0.0001), followed by hyperhomocysteinemia in all groups. In early abortions, there was no statistically significant difference with genetic mutations; instead, in late-term abortions only found such a difference with gene G20210A prothrombin and 5-10 MTHFR. In women with postpartum deep venous thrombosis mutations at gene prothrombin G20210A had the highest statistical significance; followed by IL, RPCa, HHcy and factor V de Leiden gene mutation.
Conclusions: The lupic inhibitor was the most related with recurrent miscarriages and post-partum deep venous thrombosis. We found no relationship between recurrent miscarriages and factor V Leiden, but we found relation with gen prothrombin G20210A only in late-term abortions and venous thrombosis at puerperium postpartum.

REFERENCES

1. Hatem AM, Zarko A. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Human Reproduction 2000;15:1830-1833.

2. Drucilla R, Schwartz RS. Clotting and hemorrhage in the placenta: a delicate balance. N Engl J Med 2002;347:57-59.

3. Hossain N, Paidas MJ. Inherited thrombophilia: diagnosis and anticoagulation treatment in pregnancy. Clin Lab Med 2013;33:377-390.

4. Van den Boogaard E, et al. Number and sequence of preceding miscarriages and maternal age for the prediction of antiphospholipid syndrome in women with recurrent miscarriage. Fertil Steril 2013;99:188-192.

5. Andreoli L, et al. Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. J Autoimmunity 2012;38:J197-J198.

6. Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.

7. Pengo V, Tripodi A, Reber G, et al. On behalf of the scientific and standardization committee on lupus anticoagulant phospholipid dependent antibodies. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009;7:1737-1740.

8. Lockshin MD. Pregnancy and antiphospholipid syndrome. Am J Reprod Immunol 2013;69:585-587.

9. Letter to the editor. Catastrophic antiphospholipid syndrome in the obstetric period. Eur J Obstet Gynecol Reprod Biol 2012;160:236-240.

10. Schlembach D, et al. SAF catastrófico: una complicación severa del embarazo. Int J Womens Cardiovasc Health 2012;2:240-339.

11. Destefano K, Belogolovkin V, Salihu H, Quintero R. Does anti-β2glicoproteína I improve the detection rate of antiphospholipid syndrome in pregnancy? Am J Obstet Gynecol 2008;199:S153.

12. Willis R, Pierangeli SS. Anti-β2-glycoprotein I antibodies. Ann N Y Acad Sci 2013; 1285:44-58.

13. Samarkos M, Mylona E, Kapsimali V. The role of complement in the antiphospholipid syndrome: a novel mechanism for pregnancy morbidity. Sem Arthritis Rheum 2012; 42:66-69.

14. Cervera R, Espinosa G. The antiphospholipid syndrome: 30 years in the Forefront (1983-2013) Is the GAPSS the best score? Rheumatology 2013;52:1347-1348.

15. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to B2glycoprotein I, prothrombin and risk of thrombosis. J Thromb Haemost 2005;3:1231-1235.

16. Pengo V, Ruffati A, Legnani C, et al. Clinical course of highrisk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010;8:237-242.

17. Bereczky Z, et al. Interaction between homocysteine and lipoprotein (a) increases the risk of coronary sclerosis and myocardial infarction in women. Thrombosis Research (Selected oral communication). 2009;123:S131-S137.

18. Middeldorp S. Thrombophilia and pregnancy complications: cause or association? J Thromb Haemost 2007;5(Suppl. 1):276-282.

19. Yenicesu GI, et al. A prospective case-control study analyzes 12 thrombophilic gene mutations in Turkish couples with recurrent pregnancy loss. Am J Reprod Immunol 2010;63:126-136.

20. Ocak Z, Özlü T, Ozyurt O. Association of recurrent pregnancy loss with chromosomal abnormalities and hereditary thrombophilias. Afr Health Sci 2013;13:447-452.

21. Ozdemir O, et al. Recurrent pregnancy loss and its relation combined parenteral thrombophilic gene mutations. Genet Test Mol Biomarkers 2012;16:279-286.

22. Habibovic Z, et al. Effects of inherited thrombophilia in women with recurrent pregnancy loss. Clin Exp Obstet Gynecol 2011;38:347-350.

23. Yildis G, et al. Inherited thrombophilia with recurrent pregnancy loss in Turkish women--a real phenomenon? Ginekol Pol 2012;83:598-603.

24. D’Uva M, et al. Hyperhomocysteinemia in women with unexplained sterility or recurrent early pregnancy loss from Southern Italy: a preliminary report. Thrombosis J 2007;5:10.